| Identification | Back Directory | [Name]
U-46619 | [CAS]
56985-40-1 | [Synonyms]
U-46619
9,11-Methanoxy-PGH2
9,11-Methanoepoxy PGH2
11α,9α-Epoxymethanoprostaglandin H2
U-46619 - CAS 56985-40-1 - Calbiochem
9,11-DIDEOXY-11ALPHA,9ALPHA-EPOXYMETHANO
4-alpha,5-beta(z),6-alpha(1e,3s*)))-r-(1-alph
9,11-dideoxy-11A,9A-epoxymethano-*prostaglandin F
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin f2α
9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOEPOXY PGF2ALPHA
9,11-DIDEOXY-11A,9A-EPOXYMETHANO-*PROSTA GLANDIN F2A
9a,11a-methanoepoxy-15-hydroxyprosta-5,13-dienoicacid
9,11-dideoxy-11alpha,9alpha-epoxymethanoprostaglandin F2a
9,11-DIDEOXY-11Α,9Α-EPOXYMETHANOPROSTAGLANDIN F2Α,SOLUTION
9,11-dideoxy-11alpha,9alpha-epoxymethano prostaglandin F2A S
9,11-Dideoxy-9α,11α-methanoepoxyprostaglandin F2α Solution
9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOEPOXYPROSTAGLANDIN F2ALPHA
9,11-DIDEOXY-11ALPHA,9ALPHA-EPOXY-METHANOPROSTAGLANDIN F2ALPHA
9,11-DIDEOXY-9ALPHA, 11ALPHA-METHANOEPOXY-PROSTA-5Z,13E-DIEN-OIC ACID
9,11-DIDEOXY-9ALPHA, 11ALPHA-METHANOEPOXY-PROSTA-5Z,13E-DIEN-1-OIC ACID
7-(6-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-5-yl)-5-heptenoicaci(1
(Z)-7-[(1R,4S)-6β-[(E,S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5α-yl]-5-heptenoic acid
(5Z)-7-[(1R,4S)-6β-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]heptan-5α-yl]-5-heptenoic acid
(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2 -oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid
5-Heptenoic acid, 7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl]-, (5Z)- | [Molecular Formula]
C21H34O4 | [MDL Number]
MFCD00135238 | [MOL File]
56985-40-1.mol | [Molecular Weight]
350.49 |
| Chemical Properties | Back Directory | [Boiling point ]
519.7±30.0 °C(Predicted) | [density ]
1.092±0.06 g/cm3(Predicted) | [Fp ]
-10 °C | [storage temp. ]
-20°C | [solubility ]
≥100 mg/mL in DMSO, ≥100 mg/mL in Ethanol, ≥100 mg/mL in DMF, ≥2 mg/mL in PBS pH 7.2 | [form ]
solution
| [pka]
4.76±0.10(Predicted) | [color ]
Colorless to light yellow | [BRN ]
4267334 |
| Hazard Information | Back Directory | [Uses]
U 46619 is a PGH2 analog that may be used as a thromboxane A2 (TP) receptor agonist affecting mitogenic growth of vascular smooth muscle in humans. | [Biological Activity]
PGH 2 (TXA 2 ) analog that is a potent and stable thromboxane A 2 (TP) receptor agonist (EC 50 = 0.035 μ M). Potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations. Activates ERK-1 and ERK-2 in HEK-293 cells expressing TP α and TP β receptors. | [Biochem/physiol Actions]
Thromboxane receptor agonist. | [in vitro]
u46619 showed a biphasic effect on human platelets. shape change and mlcp occurred at low concentrations of this compound (ec50 = 0.035 um and 0.057 um), whereas serotonin release, platelet at higher concentrations (ec50 = 0.536 um and 1.31 um). the effect on platelet shape change and mlcp is receptor mediated [3]. | [in vivo]
u46619, through activation of eta and etb receptors, elicits renal cortical vasoconstriction and medullary vasodilation in the rat [2]. in conscious shr (spontaneously hypertensive rats), 1-100 nmol/kg u-46619 (i.c.v.) induced a dose-related increase in blood pressure but had no significant effect on heart rate [1]. | [storage]
Store at -20°C | [References]
[1] sirén al, svartstrm-fraser m, paakkari i. central cardiovascular effects of the endoperoxide analogue u-46619 in rats. prostaglandins leukot med. 1985 mar; 17 (3): 381-6.
[2] hantz h, adesuyi a, adebayo o. differential effects of u46619 on renal regional hemodynamics in the rat: involvement of endothelin. j pharmacol exp ther. 2001 oct; 299 (1): 372-6.
[3] morinelli ta1, niewiarowski s, daniel jl, smith jb. receptor-mediated effects of a pgh2 analogue (u 46619) on human platelets. am j physiol. 1987 nov; 253 (5 pt 2): h1035-43. |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|